



Deliver safe and effective oncology therapies at home.

Current Health enables Care at Home for patients undergoing chemotherapy, CAR-T, BiTe, or BMT therapies.



Supporting higher-acuity patients outside of the hospital

Reduce inpatient stays, nosocomial infection risks, and care costs with reliable support services and technology.

 **Detect early signs** of life-threatening complications like CRS sooner¹ with our integrated technology and clinical monitoring services that enable RPM.

 **Connect with patients** via Current Health app offering messaging, symptom surveys, appointment reminders, video visits, and more.


 **Access** our unified clinical dashboard to gain a comprehensive view of patient health.

 **Mitigate risk** with our configurable condition-specific escalation pathways for timely alerts tailored to oncology care scenarios.

 **Integrate seamlessly** with existing EHR and preferred record system for patient data.

Configurable device kits for oncology

Our trusted ecosystem of connected devices enables care teams to continuously monitor the needs of each patient.



Clinical monitoring

24/7 clinical monitoring support that expands capacity through first-line triage and escalation from expert nurses and medical assistants.



Flexible pathway for outpatient CAR-T

Pre-infusion

Clinic visit and enrollment

Adele, a 51 year-old CAR-T candidate is enrolled in the program, and receives her device kit.

Virtual device activation

Adele submits baseline stats and completes assigned tasks via the Current Health app.

15-30 day post-infusion period

Monitoring and reporting

Adele logs symptoms while wearable tracks vital signs, data integrated into EHR for provider visibility.

Adverse event management

Adele's wearable detects early signs of CRS alerting clinical monitoring services team to escalate the case and triage patient.

Graduation

Upon symptom alleviation and program completion she is discharged, and kit is returned for reprocessing.



Our Impact

Sarah Cannon, the Cancer Institute of HCA Healthcare faced an increasing volume of potentially high-acuity cases and limited inpatient capacity.

Sarah Cannon's CAR-T program demonstrated the possibilities for care-at-home.

 **75%²**
of all CAR-T therapies shifted to outpatient settings

 **1,200+²**
hospital bed days saved in the first 100 patients in the program

 **17%²**
of patients avoided hospitalization

 **2.3-minute²**
average response time reported by Clinical monitoring team

 **25-minute²**
resolution time for alarms

 **4-day²**
average inpatient stay down from 16-day average for CAR-T therapy

¹ Internal data on file. Best Buy Health, 2024. Detection of the initial episode of cytokine release syndrome (CRS) using wearable monitoring occurred 2.1 hours earlier than standard of care.

² Data provided by Sarah Cannon, published in: Sarah Cannon Moves More Than 75% of CAR-T Therapies to Outpatient Setting. Best Buy Health, 2024.